* Says receives going concern notice from auditors
* Q4 shr/loss $0.52 vs. est loss/shr $0.77
* Q4 rev $5.0 mln vs. est $1.9 mln
* Shrs down 25 pct in after-hours trade
March 16 (Reuters) - Molecular Insight Pharmaceuticals Inc MIPI.O posted a narrower-than-expected quarterly loss, but said its auditors have expressed doubts on its ability to continue as a going concern, partly due to recurring losses from its operations.
Shares of the biopharmaceutical company fell almost 25 percent to $1.26 in after-market trade. They had closed at $1.76 Tuesday on Nasdaq.
The company said it would be in breach of the minimum liquidity requirements under the indenture governing its senior secured bonds in the second half of 2010, if it is unable to raise sufficient additional capital.
For the fourth quarter, the company posted a net loss of $13.2 million, or 52 cents a share, compared with a loss of $15.8 million, or 63 cents a share, a year ago.
Revenue for the quarter was $5.04 million, compared with $237,000 in the prior-year quarter.
Analysts on average were expecting the company to post a net loss of 77 cents on revenue of $1.9 million, according to Thomson Reuters I/B/E/S.
As of Dec. 31 2009, the company had about $64.0 million in cash, cash equivalents, and short-term investments, and $186.5 million of senior secured bonds and accrued and unpaid interest. (Reporting by Krishnakali Sengupta in Bangalore; Editing by Jarshad Kakkrakandy)
Our Standards: The Thomson Reuters Trust Principles.